Get ready to rewrite the rules

with Jérémie Parot, PhD, Research Scientist, SINTEF

In this episode, we explore the difficulties faced when characterizing mRNA and the opportunities that mRNA research brings to medicine.

with Adam Crowe, PhD, Sr. Manager, Analytical Development, Precision NanoSystems ULC (part of Cytiva)

In this episode, we take a deep dive into the importance of ionizable lipids in lipid nanoparticles (LNPs) and why new analytical workflows are needed for this expanding field.

with Rebecca Young, PhD, Sr. Scientist I, RNA Sciences, Aldevron

In this episode, we explore self-amplifying RNA (saRNA), its benefits and how R&D and process development teams utilize this new in vitro transcribed RNA.

with Kristen Nields, PhD, Senior Scientist, Janssen

In this episode, we explore the challenges in charge variant analysis and how to address the bottlenecks with new workflow approaches.

with Tyler Heibeck, PhD, Principal Scientist, Sutro Biopharma

In this episode, we talk about the surprises and challenges encountered in drug development and how new analytical approaches may help find the answer.

with Mike McKinnon, Senior Scientist II, Novartis

In this episode, we discuss the challenges of new modalities and how new analytical methods can address the evolving challenges in biotherapeutic characterization.

with Anita Liu, Associate Principal Scientist, Merck

In this episode, we take a look at the benefits of intact protein analysis and how to address challenges with new drug modalities.

with Jill Bradley-Graham, PhD, Senior Scientist, Gene and Cell Therapy BioAnalytics, Sanofi

In this episode, we discuss why viral vector characterization is particularly challenging and how collaboration is key for newly emerging fields.

with Shane Karnik, Senior Laboratory Director, Aliri Bioanalysis

In this episode, we discuss what bioanalysis is and how bioanalysis of oligonucleotides differs from that of other modalities.

with Thomas Kofoed, PhD, Co-founder and CEO, Alphalyse

In this episode, we chat about host cell proteins (HCPs), the importance of their analysis in cell and gene therapy products and the challenges of this field.

with Hugo Gagnon,  PhD, Chief Scientific Officer, Allumiqs

In this episode, we take a deep dive into what gene editing is and uncover why establishing analytics for gene editing is such a complex task.